Vimarsana
Biggest News Aggregation in the World

Stroke Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stroke Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stroke Study Today - Breaking & Trending Today

Individual Ability to Be Mobile in Community Tied to Cognitive Function - Vimarsana News

Individual Ability to Be Mobile in Community Tied to Cognitive Function

Community mobility is significantly associated with cognitive function in older adults, according to a study published online.

Individual Ability to Be Mobile in Community Tied to Cognitive Function - Vimarsana News

Individual Ability to Be Mobile in Community Tied to Cognitive Function

Community mobility is significantly associated with cognitive function in older adults, according to a study published online.

High BP in childhood may raise risk of heart attack, stroke: Study. - Vimarsana News

High BP in childhood may raise risk of heart attack, stroke: Study.

High bp in childhood may raise risk of heart attack, stroke: study

Algernon NeuroScience and the Centre for Human Drug - Vimarsana News

Algernon NeuroScience and the Centre for Human Drug

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT:...

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset - Vimarsana News

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it plans to move forward with its intravenous formulation of its AP-188 (“N,N-Dimethyltryptamine” or “DMT”) stroke research program as its lead asset, after having sold its Ifenprodil research program for USD $2M cash and a 20% common share

Source: yahoo.com